PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

| Applicant's or agent's file reference 316T-002710PC | FOR FURTHER ACTION | | form PCT/ISA/220 re applicable, item 5 below. | | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|---------------------------------------|-----------------------------------------------------------------------------------|--|--|
| International application No. PCT/US05/20992 | International filing date (day/ 14 June 2005 (14.06.2005) | month/year) | (Earliest) Priority Date (day/month/year) 17 June 2004 (17.06.2004) | | |
| Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | | | | | |
| This international search report has been according to Article 18. A copy is being This international search report consists o It is also accompanied | transmitted to the Internationa | al Bureau. | · | | |
| Basis of the Report a. With regard to the language, the international a | nternational search was carried | | | | |
| a translation of the | e international application into mished for the purposes of inter | | , which is the language | | |
| b. With regard to any nucleotide | e and/or amino acid sequence | disclosed in the | international application, see Box No. I. | | |
| 3. Unity of invention is lacking 4. With regard to the title, the text is approved as submitted. | • |)ws: | | | |
| | ccording to Rule 38.2(b), by th | - | it appears in Box No. IV. The applicant eport, submit comments to this Authority. | | |
| 6. With regard to the drawings, a. the figure of the drawings to be pub as suggested by the app as selected by this Auth as selected by this Auth | olished with the abstract is Figu olicant. hority, because the applicant fa nority, because this figure bette | ire No. <u>1</u> iled to suggest a | ı figure. | | |
| b. none of the figures is to be published with the abstract. | | | | | |

Form PCT/ISA/210 (first sheet) (April 2005)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US05/20992

| A. CLA IPC(8): | | | | |
|---------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|--|
| USPC: According to | | | | |
| p FIFI | DS SEARCHED | | • | |
| Minimum do | B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S.: 514/303, 338, 339 | | | |
| Documentati | on searched other than minimum documentation to the | extent that such documents are included in | the fields searched | |
| EAST, Medi | | e of data base and, where practicable, search | n terms used) | |
| | UMENTS CONSIDERED TO BE RELEVANT | | Relevant to claim No. | |
| Category * | Citation of document, with indication, where a | | 1-18, 28-39 | |
| Y A | CHEN et al., "Inactivation of Adenosine A2A Reception Amphetamine-Induced Behavioral Sensitization" in 28, pages 1086-1095 | ntors Selectively Attenuates Neuropsychopharmacology, 2003, vol. | 19-27, 40-50 | |
| Y | ACQUAS et al., New ops) who primiting to 65% 2002; 101 21% P-5-0 102 | | 1-18, 28-39 | |
| A | | | 19-27, 40-50 | |
| Y | 1 | | j | |
| | j. | | | |
| ļ | <u>;</u> | | | |
| | documents are listed in the continuation of Box C. | See patent family annex. | | |
| | pecial categories of cited documents: | "T" later document published after the inter | national filing date or priority | |
| • | defining the general state of the art which is not considered to be of | date and not in conflict with the applica principle or theory underlying the inven | tion | |
| | olication or patent published on or after the international filing date | "X" document of particular relevance; the cl considered novel or cannot be considered when the document is taken alone | aimed invention cannot be ed to involve an inventive step | |
| "L" document establish th specified) | which may throw doubts on priority claim(s) or which is cited to he publication date of another civition or other special reason (as | "Y" document of particular relevance; the cl considered to involve an inventive step combined with one or more other such | when the document is documents, such combination | |
| "O" document | referring to an oral disclosure, use, exhibition or other means | being obvious to a person skilled in the | art | |
| priority da | priority date claimed | | | |
| Date of the actual completion of the international search Date of mailing of the international search report | | | | |
| 9 March 2007 (29.03.2007) James and mailing address of the ISA/IIS Authorized officer | | | | |
| Mail Com P.O. | ling address of the ISA/US Stop PCT, Attn: ISA/US missioner for Patents Box 1450 andria, Virginia 22313-1450 | Sreeni Padmanabhan Phil. Telephone No | Jack 2 | |
| Facsimile No. | (571) 273-3201 | | | |

| | PATENT COOPERATION TREAT |
|----------------------------------|--------------------------|
| From the INTERNATIONAL SEARCHING | AUTHORITY |
| То: | |

PCT

| QUINE INTELLECTUAL PROPERTY L | AW GROUP, P.C. | | | |
|------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------|-------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|---|
| P.O BOX 458 | | WRITTEN OPINION OF THE | | |
| ALAMEDA, CA 94501 | | INTERNATIONAL SEARCHING AUTHORITY | | |
| | | (PCT Rule 43bis.1) | | |
| | | Date of mailing (day/month/year | , 2 0 APR 200 7 , | |
| Applicant's or agent's file reference | | | FOR FURTHER ACTION See paragraph 2 below | |
| 316T-002710PC | | See paragraph 2 below | | |
| International application No. | International filing date | (day/month/year) | Priority date (day/month/year) | |
| | 14 June 2005 (14.06.200 | | 17 June 2004 (17.06.2004) | |
| International Patent Classification (IPC) or | both national classificati | ion and IPC | | ĺ |
| IPC(8): Please See Continuation Sheet USPC: 514/303,338,339 | | | | |
| Applicant | | | | |
| THE REGENTS OF THE UNIVERSITY (| OF CALIFORNIA | | | j |
| I. This opinion contains indications relati | ing to the following items | s: | | |
| Box No. I Basis of the o | pinion | | | |
| Box No. II Priority | | | | ļ |
| Box No. III Non-establish | ment of opinion with reg | gard to novelty, inv | entive step and industrial applicability | |
| Box No. IV Lack of unity | of invention | | | : |
| | ement under Rule 43bis. citations and explanation | | to novelty, inventive step or industrial statement | |
| Box No. VI Certain docum | nents cited | | | |
| Box No. VII Certain defect | s in the international app | dication | | |
| Box No. VIII Certain observ | Box No. VIII Certain observations on the international application | | | |
| 2. FURTHER ACTION | | | | |
| If a demand for international preliminal | Authority ("IPEA") exc IPEA and the chosen II | cept that this does PEA has notified t | I be considered to be a written opinion of the s not apply where the applicant chooses an the International Bureau under Rule 66.1bis(b) dered. | |
| If this opinion is, as provided above, c IPEA a written reply together, where ap of Form PCT/ISA/220 or before the exp | ppropriate, with amendm | nents, before the ex | PEA, the applicant is invited to submit to the expiration of 3 months from the date of mailing whichever expires later. | |
| For further options, see Form PCT/ISA/ | 220. | | | |
| 3. For further details, see notes to Form PC | T/ISA/220. | | | |
| Name and mailing address of the ISA/US | Date of completion | on of this opinion | Authorized officer | |
| Mail Stop PCT, Attn: ISA/US Commissioner for Patents | 29 March 2007 (2 | 29.03.2007) | Sreeni Padmanabhan, PhD., | |
| P.O. Box 1450 | P.O. Box 1450 | | | |
| Alexandria, Virginia 22313-1450 Telephone No C | | | | |

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/US05/20992

| Box No. I Basis of this opinion | | | |
|---------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|
| | | | |
| 1. With | regard to the language, this opinion has been established on the basis of: | | |
| | the international application in the language in which it was filed | | |
| | a translation of the international application into, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)). | | |
| 2. With inven | regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed ation, this opinion has been established on the basis of: | | |
| a. | type of material | | |
| | a sequence listing | | |
| | table(s) related to the sequence listing | | |
| b. | format of material | | |
| | on paper | | |
| | in electronic form | | |
| c. | time of filing/furnishing | | |
| | contained in the international application as filed. | | |
| | filed together with the international application in electronic form. | | |
| | furnished subsequently to this Authority for the purposes of search. | | |
| | | | |
| 3. | In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished. | | |
| 4. Additio | one i comments: | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

10



International application No. PCT/US05/20992

| 1. Statement | | - | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Novelty (N) | Claims 1-50 | | YES |
| | Claims NONE | | NO |
| Inventive step (IS) | Claims 19-27, | 40-50 | YES |
| inventive step (10) | Claims 1-18, 2 | | NO |
| Industrial applicability (IA) | Claims 1-50 | | YES |
| industrial application (177) | Claims NONE | | NO |
| 2. Citations and explanations: Claims 19-27 and 40-50 meet the criteria set out in | PCT Article 33(2)-(3), b | ecause the prior art does no | t teach or fairly suggest the |
| nerein claimed composition and the method of scre | ening a compound for in | hibit addictive behavior. | |
| | | amphetamine-induced beha | vorial sensitization. Chen et al. |
| et al. teaches the inactivation of adenosine A2A reculso suggests that AdenosineA2A receptor antagoni Acquas et al. teaches that the herein claimed compt twould have been obvious to one of ordinary skill including SCH 58261, in a method of treating substance and account of the amphetamine-industrial contents. | sis may have the same e und SCH 58261 as select in the art at the time of it ance abuse, such as ampuced behavioural sensiti | ffect on substance abuse. stive Adenosine A2A recept nvention to employ any ade hetamine addiction, since the zation. | nosine A2A antagonist, le inactivation of Adenosine |
| also suggests that AdenosineA2A receptor antagonal Acquas et al. teaches that the herein claimed composition would have been obvious to one of ordinary skill including SCH 58261, in a method of treating substance. | sis may have the same e und SCH 58261 as select in the art at the time of it ance abuse, such as ampuced behavioural sensiti | ffect on substance abuse. stive Adenosine A2A recept nvention to employ any ade hetamine addiction, since the zation. | nosine A2A antagonist, le inactivation of Adenosine |
| also suggests that AdenosineA2A receptor antagonic Acquas et al. teaches that the herein claimed composit would have been obvious to one of ordinary skill including SCH 58261, in a method of treating substact A2A receptor would attenuate the amphetamine-induction of the state of the content of the state of the content of the state of the sta | sis may have the same e und SCH 58261 as select in the art at the time of it ance abuse, such as ampuced behavioural sensiti | ffect on substance abuse. stive Adenosine A2A recept nvention to employ any ade hetamine addiction, since the zation. | nosine A2A antagonist, le inactivation of Adenosine |
| also suggests that AdenosineA2A receptor antagonic Acquas et al. teaches that the herein claimed composition would have been obvious to one of ordinary skill including SCH 58261, in a method of treating substact A2A receptor would attenuate the amphetamine-industrial Claims 1-50 meet the criteria set out in PCT Article | sis may have the same e und SCH 58261 as select in the art at the time of it ance abuse, such as ampuced behavioural sensiti | ffect on substance abuse. stive Adenosine A2A recept nvention to employ any ade hetamine addiction, since the zation. | nosine A2A antagonist, le inactivation of Adenosine |
| also suggests that AdenosineA2A receptor antagonic acquaset al. teaches that the herein claimed composition would have been obvious to one of ordinary skill including SCH 58261, in a method of treating substact are receptor would attenuate the amphetamine-industrial states are substacted in the substacted for the substacted in the substacted for the substacted forest for the substacted for the substacted for the substacted fore | sis may have the same e und SCH 58261 as select in the art at the time of it ance abuse, such as ampuced behavioural sensiti | ffect on substance abuse. stive Adenosine A2A recept nvention to employ any ade hetamine addiction, since the zation. | nosine A2A antagonist, le inactivation of Adenosine |
| also suggests that AdenosineA2A receptor antagonic acquaset al. teaches that the herein claimed composition would have been obvious to one of ordinary skill including SCH 58261, in a method of treating substact are receptor would attenuate the amphetamine-industrial states are substacted in the substacted for the substacted in the substacted for the substacted forest for the substacted for the substacted for the substacted fore | sis may have the same e und SCH 58261 as select in the art at the time of it ance abuse, such as ampuced behavioural sensiti | ffect on substance abuse. stive Adenosine A2A recept nvention to employ any ade hetamine addiction, since the zation. | nosine A2A antagonist, le inactivation of Adenosine |
| also suggests that AdenosineA2A receptor antagonic acquaset al. teaches that the herein claimed composition would have been obvious to one of ordinary skill including SCH 58261, in a method of treating substact are receptor would attenuate the amphetamine-industrial states are substacted in the substacted for the substacted in the substacted for the substacted forest for the substacted for the substacted for the substacted fore | sis may have the same e und SCH 58261 as select in the art at the time of it ance abuse, such as ampuced behavioural sensiti | ffect on substance abuse. stive Adenosine A2A recept nvention to employ any ade hetamine addiction, since the zation. | nosine A2A antagonist, le inactivation of Adenosine |
| also suggests that AdenosineA2A receptor antagonic acquaset al. teaches that the herein claimed composition would have been obvious to one of ordinary skill including SCH 58261, in a method of treating substact are receptor would attenuate the amphetamine-industrial states are substacted in the substacted for the substacted in the substacted for the substacted forest for the substacted for the substacted for the substacted fore | sis may have the same e und SCH 58261 as select in the art at the time of it ance abuse, such as ampuced behavioural sensiti | ffect on substance abuse. stive Adenosine A2A recept nvention to employ any ade hetamine addiction, since the zation. | nosine A2A antagonist, le inactivation of Adenosine |
| also suggests that AdenosineA2A receptor antagonic acquaset al. teaches that the herein claimed composition would have been obvious to one of ordinary skill including SCH 58261, in a method of treating substact are receptor would attenuate the amphetamine-industrial states are substacted in the substacted for the substacted in the substacted for the substacted forest for the substacted for the substacted for the substacted fore | sis may have the same e und SCH 58261 as select in the art at the time of it ance abuse, such as ampuced behavioural sensiti | ffect on substance abuse. stive Adenosine A2A recept nvention to employ any ade hetamine addiction, since the zation. | nosine A2A antagonist, le inactivation of Adenosine |
| also suggests that AdenosineA2A receptor antagonic acquaset al. teaches that the herein claimed composition would have been obvious to one of ordinary skill including SCH 58261, in a method of treating substact are receptor would attenuate the amphetamine-industrial states are substacted in the substacted for the substacted in the substacted for the substacted forest for the substacted for the substacted for the substacted fore | sis may have the same e und SCH 58261 as select in the art at the time of it ance abuse, such as ampuced behavioural sensiti | ffect on substance abuse. stive Adenosine A2A recept nvention to employ any ade hetamine addiction, since the zation. | nosine A2A antagonist, le inactivation of Adenosine |
| also suggests that AdenosineA2A receptor antagonic acquaset al. teaches that the herein claimed composition would have been obvious to one of ordinary skill including SCH 58261, in a method of treating substact are receptor would attenuate the amphetamine-industrial states are substacted in the substacted for the substacted in the substacted for the substacted forest for the substacted for the substacted for the substacted fore | sis may have the same e und SCH 58261 as select in the art at the time of it ance abuse, such as ampuced behavioural sensiti | ffect on substance abuse. stive Adenosine A2A recept nvention to employ any ade hetamine addiction, since the zation. | nosine A2A antagonist, le inactivation of Adenosine |
| also suggests that AdenosineA2A receptor antagonic acquaset al. teaches that the herein claimed composition would have been obvious to one of ordinary skill including SCH 58261, in a method of treating substact are receptor would attenuate the amphetamine-industrial states are substacted in the substacted for the substacted in the substacted for the substacted forest for the substacted for the substacted for the substacted fore | sis may have the same e und SCH 58261 as select in the art at the time of it ance abuse, such as ampuced behavioural sensiti | ffect on substance abuse. stive Adenosine A2A recept nvention to employ any ade hetamine addiction, since the zation. | nosine A2A antagonist, le inactivation of Adenosine |

) t



International application No. PCT/US05/20992

| Supplemental Box In case the space in any of the preceding boxes is not sufficient. | |
|--------------------------------------------------------------------------------------------------------------------------------------------|--|
| Continuation of IPC: A61K 31/4439(2006.01),31/4433(2006.01),31/4436(2006.01) A61K 31/4439(2006.01),31/4433(2006.01),31/4436(2006.01) | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

11